RecruitingNot ApplicableNCT07209345

Pre-emptive Scalp Infiltration With Low-dose Flurbiprofen and Ropivacaine for Postoperative Analgesia After Craniotomy


Sponsor

Beijing Tiantan Hospital

Enrollment

216 participants

Start Date

Oct 15, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

Post-craniotomy pain is common and often associated with poor outcomes. Flurbiprofen axetil (FA) is an injectable NSAID for postoperative analgesia, however, the impact of local FA, remains elusive on post-craniotomy pain. As FA is highly lipophilic by merging into emulsified lipid microspheres, it has a high affinity to the surgical incision and inflammatory tissues to achieve targeted drug therapy and prolonged duration of action. On base of the previous report that local NSAIDs achieved therapeutic tissue concentrations despite a plasma concentration of \<5% of that of systemic administration, a low-dose of FA might be considered a preferential option for local infiltration to avoid anti-platelet related side effects, such as intra-cerebral bleeding. In this study, the investigators attempt to evaluate the clinical effects of pre-emptive scalp infiltration with low-dose FA and ropivacaine for postoperative analgesia after craniotomy.


Eligibility

Min Age: 18 YearsMax Age: 64 Years

Inclusion Criteria4

  • Age 18-64 years;
  • ASA physical status of I - II;
  • Scheduled for craniotomy under general anesthesia;
  • Anticipated tracheal extubation, recovery of consciousness and orientation within 2 hours after craniotomy.

Exclusion Criteria5

  • Glasgow Coma Scale <15;
  • Unable to use the PCIA device or comprehend the pain NRS;
  • History of opioid dependence, chronic headache or intake of any drugs with known analgesic properties within the 24 hours before surgery;
  • Any contraindication to flurbiprofen axetil, such as gastrointestinal ulcer, coagulation disorders, renal dysfunction, heart failure and ischemic heart disease;
  • History of allergy to any drug used in the study.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGFA+Ropivacaine

0.5 mL FA (50 mg; 5 mL; by Beijing Taide Pharmaceutical Co., Ltd) and 15 mL of 1% ropivacaine (Nai Le Pin 10mg/mL; by AstraZeneca AB, Sweden) diluted to a total volume of 30 mL in normal saline

DRUGRopivacaine

15 mL of 1% ropivacaine diluted to a total volume of 30 mL in normal saline


Locations(1)

Beijing Tiantan Hospital

Beijing, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07209345


Related Trials